MassMutual Private Wealth & Trust’s Bright Minds Biosciences DRUG Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$50	Buy	+1	New	+$71	﹤0.01%	2349

Other funds holding DRUG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

MassMutual Private Wealth & Trust's DRUG Position: Q3 2026 in Review

MassMutual Private Wealth & Trust opened a new position in Bright Minds Biosciences (DRUG) in Q3 2026: 1 share worth $50. The stake represents ﹤0.01% of the portfolio and ranks #2349 among its holdings.

30 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

MassMutual Private Wealth & Trust held 1 share of Bright Minds Biosciences worth $50 as of Q3 2026.
Bright Minds Biosciences was a new MassMutual Private Wealth & Trust position in Q3 2026.
Bright Minds Biosciences made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q3 2026, its #2349 holding.
30 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.